Corneal Crosslinking to Treat Progressive Keratoconus or Corneal Ectasia
Official title: Corneal Crosslinking for Treatment of Progressive Keratoconus or Ectasia: Randomized Comparison of Pulsed vs. Non-pulsed Treatment
Run by Price Vision Group · NCT07841470 · Data updated 2026-11-12
This study tests two different light durations used in corneal crosslinking to see which better helps people with keratoconus or corneal ectasia.
Quick facts
| Phase | Phase2; Phase3 |
|---|---|
| Study type | Interventional |
| Ages | 10 Years to 90 Years |
| Sex | All |
| Enrollment | 500 (estimated) |
| Sponsor | Price Vision Group Industry-sponsored |
| Locations | 1 site (Indianapolis, Indiana) |
| Status | Recruiting |
| Started | October 1, 2025 |
| Main results expected | December 31, 2030 |
| Study ends | June 30, 2031 |
| Registry record updated | September 25, 2026 |
| Trial ID | NCT07841470 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults diagnosed with keratoconus or corneal ectasia who can give informed consent and have no exclusionary ocular conditions.
✕Probably not a fit
Patients with preexisting corneal scarring in the treatment zone, active ocular surface disease, certain prior corneal conditions, or pregnancy may not benefit or may be excluded from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This randomized trial compares two variants of corneal crosslinking using riboflavin and light exposure in patients with keratoconus or corneal ectasia. Participants are assigned to either pulsed light or non-pulsed light regimens to determine which duration provides better stabilization of the cornea. The study spansPhase 2 and Phase 3, focusing on safety and efficacy in preventing disease progression. Eligible participants must have a keratoconus or corneal ectasia diagnosis and provide informed consent, with several ocular health exclusions applied. Location is Price Vision Group in Indianapolis, Indiana.
Why it matters
Potential benefit: If successful, the preferred crosslinking light duration could offer better disease stabilization and vision outcomes for patients with keratoconus or corneal ectasia.
How similar studies have gone: Prior crosslinking studies have shown potential for disease stabilization, but this trial specifically evaluates two light-duration regimens in a randomized design.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of keratoconus or corneal ectasia * Provision of written informed consent Exclusion Criteria: * Previous ocular condition in the study eye that may predispose for future complications including history of corneal disease (e.g., herpes simplex, herpes zoster keratitis, recurrent erosion syndrome, corneal melt, corneal dystrophy, etc.) * Clinically significant corneal scarring in the proposed treatment zone * History of chemical injury or delayed epithelial healing in the study eye * Known sensitivity to study medication * A current condition, including clinically significant dry eyes or use of medications know to induce dry eye symptoms, that, in the treating physician's opinion, would interfere with or prolong epithelial healing * Pregnancy (including plan to become pregnant) or lactation during the course of the study
Where it's running
-
Price Vision Group
Indianapolis, Indiana, United States Recruiting
Study contacts
- Principal investigator: Francis Price, MD — Price Vision Group
- Study coordinator: Marianne Price, PhD
- Email: mprice@cornea.org
- Phone: 317-814-2990
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Long-term follow-up for patients with corneal diseases
This study looks at how well different treatments work for people with corneal diseases like keratoconus over the long term, to see how their eyes are doing after surgery.
-
Evaluating a new system for treating corneal ectasia
This study is testing a new treatment system for people with corneal ectasia and keratoconus to see if it can help improve their eye health and vision.
-
Brillouin hydration mapping to study cornea health
Researchers test a Brillouin microscope to see if it can measure corneal water content in healthy people and those with eye conditions.
-
Same-day bilateral corneal cross-linking for keratoconus
This trial tests whether performing corneal cross-linking in both eyes on the same day is safe and feasible for people with keratoconus.
-
A Smart Aperture Lens to Help Keratoconus and Presbyopia
This study tests the NOA lens, a custom scleral contact lens with a central aperture, to see if it improves vision for people with keratoconus and presbyopia.
-
GLK-221 eye drops for keratoconus
This trial will test whether twice-daily GLK-221 eye drops are safe and help adults aged 18–55 with keratoconus compared with a placebo.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.